Latest news with #Sanofi
Business Recorder
4 hours ago
- Business
- Business Recorder
Sanofi revises annual sales growth expectations on strong Dupixent demand
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer treatments. It had previously said it expects annual sales to grow by mid-to-high single-digit percentage at constant currency rates. The drugmaker also confirmed that it expects earnings to grow at a low double-digit percentage this year. Sanofi has significantly amped up its R&D expenditure in recent years, a move that led it to abandon its long-term margin targets in 2023. This shift underscores its focus to capitalize on the success of its blockbuster drug Dupixent as it builds its next wave of growth drivers. Sales of its asthma drug Dupixent rose 21.1% to 3.83 billion euros ($4.38 billion), compared to 3.74 billion euros expected on average by analysts in a company-provided poll. Quarterly business operating income, excluding one-off items, rose by 3.3% to 2.46 billion euros, below the average analyst estimate of 2.57 billion euros in a poll posted on the company's website.
Reuters
4 hours ago
- Business
- Reuters
Sanofi raises annual sales growth expectations on strong Dupixent demand
July 31 (Reuters) - France's Sanofi ( opens new tab said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer treatments. It had previously forecast annual sales to grow by mid-to-high single-digit percentage at constant currency rates. The drugmaker confirmed it expects earnings to grow by a low double-digit percentage this year, but said the forecast now includes all expenses from its newly acquired businesses. Sanofi has significantly amped up its R&D expenditure in recent years and plans to be more active with acquisitions as it looks to build its next wave of growth drivers beyond its asthma drug Dupixent. It recently closed its up to $9.5 billion acquisition of Blueprint Medicines, a maker of rare immunology disease treatments. But investor hopes remain high for the anti-inflammatory drug Dupixent, the company's main growth driver, especially since it was approved for a common lung condition called chronic obstructive pulmonary disease last year. Sales of Dupixent, which it makes with partner Regeneron (REGN.O), opens new tab, rose 21.1% to 3.83 billion euros ($4.38 billion), compared to 3.74 billion euros expected on average by analysts in a company-provided poll. Chief Financial Officer François-Xavier Roger said that outside of the U.S., sales of the drug exceeded 1 billion euros. "We are very confident in our sales target of around 22 billion euros in 2030," Roger said about the drug. Quarterly business operating income, excluding one-off items, came in at 2.46 billion euros, below the average analyst estimate of 2.57 billion euros in a poll posted on the company's website. Sanofi said higher research costs and higher profit sharing with its partner Regeneron weighed on its earnings during the quarter. Vaccines sales rose a currency-adjusted 10% to 1.21 billion euros in the quarter, ahead of a 1.14 billion euro analyst consensus. ($1 = 0.8740 euros)
Yahoo
4 hours ago
- Business
- Yahoo
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59 Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIO Dupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launch Vaccines sales increased by 10.3% to €1.2 billion Research and Development expenses were €1.9 billion, up 17.7% Selling, general and administrative expenses were €2.3 billion, up 7.8% Business EPS was €1.59, up 8.3% at CER and up 1.9% reported; IFRS EPS was €3.24 Pipeline progress Three regulatory approvals: Dupixent BP (US), Sarclisa NDMM, TE (EU), and MenQuadfi meningitis (US) Three phase 3 readouts, incl. itepekimab COPD (one met primary endpoint/one did not); positive SP0087 in rabies prevention Seven regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology Capital allocation Sanofi and CD&R closed the Opella transaction, creating an independent global consumer healthcare leader Acquisitions completed: Blueprint, in rare diseases/immunology, and Dren Bio's DR-0201, early-stage pipeline in immunology Acquisitions announced: Vigil, in Alzheimer's disease, and Vicebio, in respiratory vaccines, adding to the early-stage pipeline3 Sustainability Sanofi ranked the world's tenth most sustainable company and number one in Pharmaceuticals & Biotechnology by TIME Guidance In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4 Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date Paul Hudson, Chief Executive Officer: 'We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses. Our pipeline continues to make progress despite the mixed results with itepekimab in COPD. We are progressing the data analysis and once finished, we will discuss with regulatory authorities. We remain steadfast in our dedication to bringing new medicines and vaccines to patients. We eagerly anticipate several important phase 3 data readouts in the second half of the year, including amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis. Earlier in July, we successfully closed the acquisition of Blueprint in rare diseases, and we are anticipating the closing of the Vigil acquisition in neurology during Q3. Sanofi will remain focused on strategically redeploying capital towards growth and differentiated science with attractive financial returns. We continue to advance our strategy as an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth.' Q2 2025 Change Change at CER H1 2025 Change Change at CER IFRS net sales reported €9,994m +6.0% +10.1% €19,889m +8.3% +9.9% IFRS net income reported €3,939m +253.9% — €5,812m +158.8% — IFRS EPS reported €3.24 +264.0% — €4.74 +163.3% — Free cash flow5 €1,429m +65.8% — €2,458m +474.3% — Business operating income €2,461m -2.4% +3.3 % €5,363m +8.6% +10.8% Business net income €1,940m -0.6% +5.1 % €4,152m +7.6% +9.8% Business EPS €1.59 +1.9% +8.3% €3.39 +9.7% +12.0% 1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the business net income, a non-IFRS financial measure (definition in Appendix 9). The income statement is in Appendix 3 and a reconciliation of net income as reported under IFRS to business net income is in Appendix 4. 3 Subject to closing conditions detailed overleaf. 4 Applying July 2025 average currency exchange rates, the currency impacts are estimated at around -4% on sales and at around -6% on business EPS. 5 Free cash flow is a non-IFRS financial measure (definition in Appendix 9). Attachment Press releaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
4 hours ago
- Business
- Reuters
Sanofi revises annual sales growth expectations on strong Dupixent demand
July 31 (Reuters) - France's Sanofi ( opens new tab said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer treatments. It had previously said it expects annual sales to grow by mid-to-high single-digit percentage at constant currency rates. The drugmaker also confirmed that it expects earnings to grow at a low double-digit percentage this year. Sanofi has significantly amped up its R&D expenditure in recent years, a move that led it to abandon its long-term margin targets in 2023. This shift underscores its focus to capitalize on the success of its blockbuster drug Dupixent as it builds its next wave of growth drivers. Sales of its asthma drug Dupixent rose 21.1% to 3.83 billion euros ($4.38 billion), compared to 3.74 billion euros expected on average by analysts in a company-provided poll. Quarterly business operating income, excluding one-off items, rose by 3.3% to 2.46 billion euros, below the average analyst estimate of 2.57 billion euros in a poll posted on the company's website. ($1 = 0.8740 euros)
Bloomberg
4 hours ago
- Business
- Bloomberg
Sanofi Profit Growth Slowed by Spending on Research
Sanofi reported lower-than-expected profit for the second quarter as the French drugmaker spent more to develop new treatments. Earnings per share excluding some items rose 1.9% to €1.59, the company said Thursday, lower than the €1.67 estimated by analysts surveyed by Bloomberg. Sales were as expected, led by new indications for the blockbuster Dupixent.
